Table 1.
Patient characteristics of those treated with 90Y for liver-dominant metastatic colorectal cancer.
| n (%) | Median | Range | |
|---|---|---|---|
| Age (years) | 64 | 37–83 | |
| Male | 35 (68.6) | ||
| Female | 16 (31.4) | ||
| Time from diagnosis of metastases to 1st Rx (months) | 23.2 | 1.3–99.9 | |
| Extrahepatic disease present | 28 (58.3) | ||
| Pulmonary nodules present | 14 (28.5) | ||
| Previous liver-directed therapy | 16 (31.4) | ||
| Previous liver resection | 12 (23.5) | ||
| Previous RFA | 11 (21.5) | ||
| Previous hepatic artery chemoinfusion | 5 (9.8) | ||
| Failed either bevacizumab or cetuximab* | 33 (73.3) | ||
| Failed both bevacizumab or cetuximab | 9 (20.0) | ||
| Failed capecitabine | 14 (31.1) |
*Those receiving both bevacizumab and cetuximab also included.